

## Special Issue

# Pediatric Cardiomyopathies: From Genotype to Phenotype

### Message from the Guest Editors

Cardiomyopathies in children are rare diseases (estimated incidence of  $\approx 1$  per 100 000 children). They are a major cause of morbidity, and major indications for heart transplantation and mortality. If we compare Children cardiomyopathy to other rare diseases (including cancers), a clear divergence is observed in terms of advances in research and dedicated scientific meetings in the latter group. The main focus of this Issue is to offer an updated landscape and increase knowledge in specific characteristics related to childhood onset cardiomyopathies and to attempt to establish personalized management workflows that can help clinicians when facing specific and sometimes “ultra-rare” cardiomyopathies in children.

---

### Guest Editors

Dr. Anwar Baban

Cardiogenetic Service, Rare Diseases and Medical Genetics Units, Bambino Gesù Children Hospital & Research Institute, IRCCS, 00165 Rome, Italy

Prof. Dr. Sabine Klaassen

Experimental and Clinical Research Center, a cooperation between the Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, and the Charité - Universitätsmedizin Berlin, Lindenberger Weg 80, 13125 Berlin, Germany

---

### Deadline for manuscript submissions

closed (28 February 2022)



## Journal of Cardiovascular Development and Disease

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.4  
CiteScore 2.6  
Indexed in PubMed



[mdpi.com/si/92190](https://mdpi.com/si/92190)

*Journal of Cardiovascular  
Development and Disease*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jcdd@mdpi.com](mailto:jcdd@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jcdd](https://doi.org/10.3390/jcdd)





# Journal of Cardiovascular Development and Disease

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.4  
CiteScore 2.6  
Indexed in PubMed



[mdpi.com/journal/  
jcdd](https://mdpi.com/journal/jcdd)



## About the Journal

### Message from the Editor-in-Chief

---

#### Editor-in-Chief

Prof. Dr. Thomas Brand  
National Heart & Lung Institute, Imperial College London, South  
Kensington Campus, London SW7 2AZ, UK

---

#### Author Benefits

##### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed,  
PMC, Embase, CAPlus / SciFinder, and other databases.

##### Journal Rank:

JCR - Q2 (Cardiac and Cardiovascular Systems) /  
CiteScore - Q2 (General Pharmacology, Toxicology and  
Pharmaceutics )

##### Rapid Publication:

manuscripts are peer-reviewed and a first decision is  
provided to authors approximately 25.7 days after  
submission; acceptance to publication is undertaken in 2.8  
days (median values for papers published in this journal in  
the second half of 2024).